JAMES C. BARTON, M.D.; MARCEL E. CONRAD, M.D.
BARTON JC, CONRAD ME. Beneficial Effects of Hepatitis in Patients with Acute Myelogenous Leukemia. Ann Intern Med. 1979;90:188-190. doi: 10.7326/0003-4819-90-2-188
Download citation file:
Published: Ann Intern Med. 1979;90(2):188-190.
Of 50 consecutive patients admitted with acute myelogenous leukemia, 30 developed complete remissions on antileukemic therapy. Nineteen of the 30 repeatedly had elevated serum glutamic oxalacetic transaminase (SGOT) concentrations 3 to 14 weeks after the start of therapy. Patients with SGOT elevations had a significantly greater chance of remission and a longer survival (76 ± 11 weeks) than those with normal SGOT levels (39 ± 5 weeks), suggesting that hepatitis may have a beneficial effect in acute myelogenous leukemia. The hepatitis was mild in all patients. Review of patients at this institution alive 2 years after the diagnosis of acute myelogenous leukemia showed that they repeatedly had elevated SGOT levels. We believe that most had non-A, non-B post-transfusion hepatitis, which may have a beneficial effect on the leukemia or serve as an indicator of patients who have greater immunocompetence and thus a better prognosis.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Hematology/Oncology, Leukemia/Lymphoma, Liver Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only